Cefetamet

MECHANISM OF ACTION

• Cefetamet had produced its antibacterial effect by disrupting the normal formation of the bacterial cell wall. After reaching the bacterial target sites, it had interacted with specific penicillin-binding proteins (PBPs) that participated in the final steps of peptidoglycan synthesis.

• By inhibiting these proteins, cefetamet had prevented proper cross-linking and strengthening of the peptidoglycan structure. The resulting cell wall had become structurally unstable and unable to withstand normal osmotic pressure. This damage had eventually resulted in bacterial cell lysis and death. Therefore, cefetamet had acted as a bactericidal antibiotic.

PHARMACOKINETICS

The pharmacokinetic behavior of cefetamet had involved the absorption of its oral prodrug, conversion to the active drug, distribution into body tissues and fluids, limited metabolism, and predominantly renal elimination.

Absorption

Cefetamet had not been efficiently absorbed when administered directly by the oral route. For this reason, cefetamet pivoxil had been used as an orally administered prodrug. After reaching the gastrointestinal tract, cefetamet pivoxil had been absorbed and subsequently hydrolyzed to release active cefetamet.

Distribution

Cefetamet has a steady-state volume of distribution of approximately 0.29 L/kg, indicating distribution mainly within extracellular body fluids. 

Metabolism

Cefetamet had undergone comparatively little metabolic alteration after reaching the circulation. In contrast, its oral prodrug, cefetamet pivoxil, had been extensively converted to cefetamet through hydrolysis.

Elimination

Cefetamet had been removed from the body mainly through the renal route. A substantial proportion of the administered active drug had been excreted through the kidneys, largely in an unchanged form. Glomerular filtration and renal tubular secretion had contributed to its clearance from the systemic circulation.

PHARMACODYNAMICS

Cefetamet was a third-generation cephalosporin that exerted its antibacterial effect by interfering with bacterial cell-wall formation. Following administration of cefetamet pivoxil, the prodrug was converted into the active cefetamet. The active drug bound to bacterial penicillin-binding proteins and disrupted the final steps involved in peptidoglycan synthesis. This weakened the bacterial cell wall and eventually caused bacterial death. Cefetamet showed activity against a range of Gram-positive and Gram-negative bacteria and had been used particularly for infections involving the respiratory and urinary tracts.

ADMINISTRATION

Cefetamet was given orally in the form of cefetamet pivoxil, which was available as tablets or an oral suspension. Administration with food was preferred because food enhanced the systemic availability of cefetamet. After absorption and conversion to the active drug, cefetamet was eliminated mainly through the kidneys. Therefore, patients with reduced renal function required appropriate adjustment of the administered dose.

DOSAGE AND STRENGTH

The commonly reported adult regimen for cefetamet pivoxil was 500 mg administered twice daily, with the doses generally separated by approximately 12 hours. In pediatric patients, the dose was determined according to body weight, and a dose of approximately 10 mg/kg had been reported. The actual dose and duration of therapy depended on the nature and severity of the infection and the patient's clinical status. Patients with impaired kidney function required a reduction or adjustment of the dose to account for decreased renal elimination.

DRUG INTERACTIONS

• Cefetamet pivoxil had demonstrated a relatively low potential for clinically important drug interactions. Studies had shown that concomitant administration with antacids or ranitidine did not produce a significant change in cefetamet absorption or elimination. N-acetylcysteine also did not produce a clinically meaningful alteration in cefetamet pharmacokinetics. Cisapride caused a modest increase in cefetamet absorption, but the change was not considered clinically significant.

• Since cefetamet was eliminated mainly through the kidneys, medicines capable of substantially altering renal function could potentially affect cefetamet exposure, particularly in individuals with existing renal impairment. Overall, the available evidence indicated that cefetamet had limited potential for clinically relevant interactions with the medicines evaluated.

FOOD INTERACTIONS 

Cefetamet could be taken either with food or on an empty stomach. Food was not considered to produce a clinically significant effect on the absorption of the drug. Taking cefetamet with meals could nevertheless have been helpful for patients who experienced stomach discomfort after administration. The medicine was generally taken according to the instructions provided for the particular formulation.

CONTRAINDICATIONS 

Cefetamet was not used in patients who had previously shown hypersensitivity to cefetamet, other cephalosporin antibiotics, or any ingredient present in the formulation. Extra care was required in patients with a history of severe allergic reactions to penicillins or other β-lactam antibiotics because allergic cross-reactivity could occur between these antibiotic groups.

SIDE EFFECTS 

Cefetamet was generally tolerated, although some patients experienced unwanted effects during treatment. The commonly reported or clinically relevant reactions included:

• Nausea or vomiting

• Diarrhea

• Abdominal pain or general stomach discomfort

• Headache

• Skin eruptions, rash, or itching

• Urticaria

• Increased or otherwise altered liver enzyme values

• Hypersensitivity reactions, which in rare cases could progress to angioedema or anaphylaxis

OVER DOSE

• Excessive administration of cefetamet could have resulted in a greater intensity of its usual adverse reactions. Gastrointestinal symptoms such as nausea, vomiting, diarrhea, and abdominal discomfort could have become more pronounced. Dizziness or neurological symptoms could also have occurred, while severe overdose in susceptible individuals could have been associated with seizures.

• Treatment of cefetamet overdose was primarily supportive and depended on the patient's clinical condition. Medical observation was required, with attention given to renal function and possible neurological complications. Any resulting symptoms were managed using appropriate supportive measures.

TOXICITY

Cefetamet had generally been considered to have a relatively low potential for toxicity when it was used within the recommended dosage range. The possibility of toxic effects increased when excessive amounts were administered or when the body's ability to eliminate the drug was reduced.